Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ayala Pharmaceuticals, Inc.ADXS · Entity 93434 | Chief Financial Officer | March 29, 2018 | April 03, 2018 |
| INSMED IncINSM · Entity 3174 | Chief Financial Officer | June 03, 2026 | June 05, 2026 |
| Latigo Biotherapeutics, Inc.LTGO · Entity 4709 | Director | August 06, 2026 | August 07, 2026 |
| ONCOSEC MEDICAL IncONCS · Entity 117092 | CFO/COO | January 16, 2020 | January 21, 2020 |
| Xilio Therapeutics, Inc.XLO · Entity 7122 | Director | June 11, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ayala Pharmaceuticals, Inc.
Report date March 29, 2018 · Filed April 03, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 226,670 |
Reported balance
After 2018-03-29 transaction · row 1
1 source rowRow 1 · 2018-03-29 · Grant · Acquired 1,088 · Balance 226,670 F1: The reporting voluntarily person purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount of 1,365 shares of which 277 shares were forfeited to pay withholding taxes associated with the stock issuance. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting voluntarily person purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount of 1,365 shares of which 277 shares were forfeited to pay withholding taxes associated with the stock issuance.
INSMED Inc
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 69,082 |
Reported balance
After 2026-06-03 transaction · row 1
1 source rowRow 1 · 2026-06-03 · Sale · Disposed 2,404 · Balance 69,082 F1: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees.
Latigo Biotherapeutics, Inc.
Report date August 06, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.16 · Expires 2036-04-06 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-08-06 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The shares subject to this option shall vest in 48 equal monthly installments after April 1, 2026. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest in 48 equal monthly installments after April 1, 2026. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
ONCOSEC MEDICAL Inc
Report date January 16, 2020 · Filed January 21, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,389 |
Reported balance
After 2020-01-16 transaction · row 1
1 source rowRow 1 · 2020-01-16 · Sale · Disposed 1,351 · Balance 41,389 F1: In connection with the vesting of 3,906 RSUs on January 16, 2020, a total of 1,351 shares were sold in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such withholding, which was conducted automatically in accordance with the issuer's corporate policies. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the vesting of 3,906 RSUs on January 16, 2020, a total of 1,351 shares were sold in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such withholding, which was conducted automatically in accordance with the issuer's corporate policies.
Xilio Therapeutics, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.99 · Expires 2036-06-10 | Direct | 5,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 5,000 · Balance 5,000 F1: The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
scPharmaceuticals Inc.
Report date October 07, 2025 · Filed October 07, 2025
Section 16 reporting ended · disclosed 2025-10-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.85 · Expires 2035-06-03 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-10-07 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, F2: (Continued from footnote 1) without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.11 · Expires 2034-06-11 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-10-07 · Disposition to issuer · Disposed 19,750 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, F2: (Continued from footnote 1) without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.53 · Expires 2032-06-14 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-10-07 · Disposition to issuer · Disposed 16,300 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, F2: (Continued from footnote 1) without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash,
F2: (Continued from footnote 1) without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2017 Filed Aug 1, 2017 16:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 280 | $6.47 | $1,811.60 |
DisclosureSEC source: 0001493152-17-008348 · form4.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,429 F1 · shares: The reporting person voluntarily purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount of 357 shares of which 77 shares were forfeited to pay withholding taxes associated with the stock issuance. Read SEC document |
| June 30, 2017 Filed Jul 3, 2017 16:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 394 | $6.49 | $2,557.06 |
DisclosureSEC source: 0001493152-17-007454 · form4.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,149 F1 · shares: The reporting person voluntarily purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount of 533 shares of which 139 shares were forfeited to pay withholding taxes associated with the stock issuance. Read SEC document |
| June 19, 2017 Filed Jun 20, 2017 18:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 57,199 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-17-006929 · form4.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,755 F1 · shares: As part of her long-term incentive compensation, the reporting person was previously granted a performance based restricted stock award by the Compensation Committee. The specific terms of performance, which were required to be achieved prior to earning the award, have now been met. These performance terms were (i) the FDA acceptance of the ADXS-NEO IND, and (ii) the opening of a certain pre-defined number of clinical sites for the AIM2CERV study prior to November 1, 2017. The award vests one-third in November 2017, one-third in November 2018, and will be fully vested in November 2019. Read SEC document |
| May 31, 2017 Filed Jun 1, 2017 16:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 219 | $8.07 | $1,767.33 |
DisclosureSEC source: 0001493152-17-006085 · form4.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,556 F1 · shares: The reporting person voluntarily purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount of 286 shares of which 67 shares were forfeited to pay withholding taxes associated with the stock issuance. Read SEC document |
| May 01, 2017 Filed May 1, 2017 17:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 57,881 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-17-004627 · form4.xml · nonDerivative · entry 2 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,337 F2 · shares: The award vests one-third on November 1, 2017, one-third on November 1, 2018, and will be fully vested on November 1, 2019. Read SEC document |
| April 28, 2017 Filed May 1, 2017 17:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 185 | $8.56 | $1,583.60 |
DisclosureSEC source: 0001493152-17-004627 · form4.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,456 F1 · shares: The reporting person voluntarily purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount of 270 shares of which 85 shares were forfeited to pay withholding taxes associated with the stock issuance. Read SEC document |
| March 31, 2017 Filed Apr 3, 2017 16:34 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 194 | $8.17 | $1,584.98 |
DisclosureSEC source: 0001493152-17-003401 · form4.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,271 F1 · shares: The reporting person voluntarily purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount of 282 shares of which 88 shares were forfeited to pay withholding taxes associated with the stock issuance. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 16:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | Tax withholdingCommon Stock | 61 | $8.79 | $536.19 |
DisclosureSEC source: 0001493152-17-002027 · form4.xml · nonDerivative · entry 2 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,077 F2 · shares: Represents shares forfeited by the reporting person in order to pay withholding taxes associated with the stock issuances. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 16:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 263 | $8.79 | $2,311.77 |
DisclosureSEC source: 0001493152-17-002027 · form4.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,138 F1 · shares: The reporting person purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 16:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | Tax withholdingCommon Stock | 56 | $8.96 | $501.76 |
DisclosureSEC source: 0001493152-17-001036 · form4.xml · nonDerivative · entry 2 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,875 F2 · shares: Represents shares forfeited by the reporting person in order to pay withholding taxes associated with the stock issuances. Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 16:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 250 | $8.96 | $2,240.00 |
DisclosureSEC source: 0001493152-17-001036 · form4.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,931 F1 · shares: The reporting person purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). Read SEC document |
| December 30, 2016 Filed Jan 3, 2017 17:28 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | Tax withholdingCommon Stock | 189 | $7.16 | $1,353.24 |
DisclosureSEC source: 0001493152-17-000063 · form4.xml · nonDerivative · entry 4 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,681 F5 · shares: Represents shares forfeited by the reporting person in order to pay withholding taxes associated with the stock issuance. Read SEC document |
| December 30, 2016 Filed Jan 3, 2017 17:28 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 427 | $7.16 | $3,057.32 |
DisclosureSEC source: 0001493152-17-000063 · form4.xml · nonDerivative · entry 3 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,870 F4 · shares: The reporting person purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). Read SEC document |
| December 30, 2016 Filed Jan 3, 2017 17:28 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | SaleCommon Stock | 5,520 | $7.37 | $40,682.40 |
DisclosureSEC source: 0001493152-17-000063 · form4.xml · nonDerivative · entry 2 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,443 F2 · shares: In connection with the vesting of 12,500 shares on December 30, 2016, a total of 5,520 of such shares were withheld by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F3 · price: Reflects the weighted average sale price. The range of prices for such transaction is $7.36 to $7.38. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 30, 2016 Filed Jan 3, 2017 17:28 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-17-000063 · form4.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,963 F1 · shares: Represents a promotional award granted to the reporting person by the Compensation Committee of the Company's Board of Directors. The awards vests one-fourth immediately, one-fourth on December 30, 2017, one-fourth on December 30, 2018, and will be fully vested on December 30, 2019. Read SEC document |
| November 30, 2016 Filed Dec 1, 2016 16:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | Tax withholdingCommon Stock | 55 | $8.31 | $457.05 |
DisclosureSEC source: 0001493152-16-015587 · form4.xml · nonDerivative · entry 2 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,963 F2 · shares: Represents shares forfeited by the reporting person in order to pay withholding taxes associated with the stock issuance. Read SEC document |
| November 30, 2016 Filed Dec 1, 2016 16:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 245 | $8.31 | $2,035.95 |
DisclosureSEC source: 0001493152-16-015587 · form4.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,018 F1 · shares: The reporting person purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). Read SEC document |
| November 03, 2016 Filed Nov 7, 2016 16:31 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantOption · Derivative | 68,906 | $0.00 Strike: $7.71 | $0.00 |
DisclosureSEC source: 0001493152-16-014578 · form4.xml · derivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,906 Underlying: Common Stock · 68,906 shares Expires 2026-11-03 F1 · shares: This award relates to the annual long term incentive grant awarded by the Compensation Committee following the completion of our 2016 Fiscal Year and is subject to the terms of our 2015 Incentive Plan. The award vests one-third on November 3, 2017, one-third on November 3, 2018, and will be fully vested on November 3, 2019. Read SEC document |
| October 31, 2016 Filed Nov 2, 2016 16:40 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | Tax withholdingCommon Stock | 56 | $8.09 | $453.04 |
DisclosureSEC source: 0001493152-16-014444 · form4.xml · nonDerivative · entry 2 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,773 F2 · shares: Represents shares forfeited by the reporting person in order to pay withholding taxes associated with the stock issuance. Read SEC document |
| October 31, 2016 Filed Nov 2, 2016 16:40 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 252 | $8.09 | $2,038.68 |
DisclosureSEC source: 0001493152-16-014444 · form4.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,829 F1 · shares: The reporting person purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 18:28 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | Tax withholdingCommon Stock | 43 | $10.69 | $459.67 |
DisclosureSEC source: 0001493152-16-013846 · form4.xml · nonDerivative · entry 2 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,577 F2 · shares: Represents shares forfeited by the reporting person in order to pay withholding taxes associated with the stock issuance. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 18:28 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 191 | $10.69 | $2,041.79 |
DisclosureSEC source: 0001493152-16-013846 · form4.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,620 F1 · shares: The reporting person purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.